Harvard Bioscience Inc. announced a new retention agreement with Mark Frost, the company's Interim Chief Financial Officer, on August 12, 2025. Under the agreement, Mr. Frost is eligible for a $100,000 cash bonus upon the successful refinancing of the company's existing term loan and senior revolving credit facility by March 15, 2026. This bonus replaces the previously offered $50,000 bonus as per his offer letter dated April 10, 2025. If Mr. Frost is terminated without cause before the refinancing date, he will receive his base salary and the company's portion of COBRA premiums for five months, contingent upon signing a general release of claims.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.